Galena Biopharma Presented Two Posters at the San Antonio Breast Cancer Symposium
Dec 12, 2016 12:05 pm UTC| Business
NeuVax™ (nelipepimut-S) Phase 2 VADIS trial design in women with ductal carcinoma in situ (DCIS)GALE-301 and GALE-302 Phase 1b clinical data in breast cancer patients SAN RAMON, Calif., Dec. 12, 2016 -- Galena...
Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin
Dec 12, 2016 12:01 pm UTC| Business
-- EPIC registration trial successfully achieves FDA primary endpoints in patients with complicated urinary tract infections (cUTI) -- -- EPIC demonstrates superiority on EMA primary endpoints -- -- CARE descriptive...
Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin
Dec 12, 2016 12:01 pm UTC| Business
-- EPIC registration trial successfully achieves FDA primary endpoints in patients with complicated urinary tract infections (cUTI) -- -- EPIC demonstrates superiority on EMA primary endpoints -- -- CARE descriptive...
Inspyr Announces Private Placement of $1.0 Million
Dec 12, 2016 12:00 pm UTC| Business
WESTLAKE VILLAGE, Calif., Dec. 12, 2016 -- Inspyr Therapeutics (OTCQB:NSPX) (“Inspyr” or the “Company”), a biotech company developing novel prodrug therapeutics for the treatment of cancer, today announced that it has...
Dec 12, 2016 12:00 pm UTC| Business
Patient focused webinar titled “Stem Cell Transplants for Acute Myeloid Leukemia: What you Need to Know”Webinar to be led by transplant expert, Dr. Patrick Stiff, Director of the Cardinal Bernardin Cancer Center at Loyola...
Dec 12, 2016 12:00 pm UTC| Business
NEW YORK, Dec. 12, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative...
Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin
Dec 12, 2016 12:00 pm UTC| Business
GAITHERSBURG, Md., Dec. 12, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its botulism antitoxin, BAT® [Botulism Antitoxin...